PeptideDeepDiveCJC-1295 vs Ipamorelin: Mechanism, Evidence & Safety
CJC-1295 and ipamorelin act through different growth-hormone signalling pathways. This comparison explains receptor mechanism, human evidence, duration, safety gaps, the untested combination, and current FDA, WADA and UK/EU status.
In this comparison
CJC-1295 vs Ipamorelin: short answer
The main difference is receptor pathway and duration. CJC-1295 with DAC is a long-acting GHRH analogue, while ipamorelin is a shorter-acting ghrelin-receptor agonist. Human studies show hormone-level effects for each compound separately, but no controlled human trial has established recovery, physique or anti-ageing benefits for the pair, and no controlled trial has validated the popular combination itself.
| Category | CJC-1295 with DAC | Ipamorelin |
|---|---|---|
| Compound class | A long-acting GHRH analogue. | By contrast, a short-acting peptide that triggers the ghrelin receptor. |
| Receptor | The GHRH receptor on pituitary somatotroph cells. | Meanwhile, the ghrelin receptor, also called GHSR-1a. |
| Core signal | Extends a GHRH-like signal for growth hormone release. | In comparison, produces a short, dose-linked growth hormone episode. |
| Human half-life | About 5.8–8.1 days for the long-acting form studied in 2006. | However, about two hours in a 1999 healthy-volunteer infusion study. |
| Human evidence | Early human studies measured GH, IGF-1 and pulse patterns. | In addition, early human GH research and a later bowel-surgery study. |
| Stack evidence | Nevertheless, no controlled human trial has tested CJC-1295 and ipamorelin together. | |
| Medicine status | Therefore, no EU-wide approval and no FDA approval. | Similarly, no EU-wide approval and no FDA approval. |
| Sport status | WADA names it among GHRH analogues. | Moreover, WADA names it among growth hormone secretagogues. |
CJC-1295 vs Ipamorelin mechanism: GHRH analogue vs GHRP
CJC-1295 acts through the GHRH receptor
First, CJC-1295 copies part of the signal made by growth hormone-releasing hormone. It triggers GHRH receptors on GH-producing pituitary cells. As a result, the pituitary releases more growth hormone, which can then affect IGF-1 levels.
Also, the Drug Affinity Complex, or DAC, changes how long the peptide lasts. In simple terms, DAC binds the peptide to albumin in the blood. Therefore, albumin binding slows removal and helps explain the multi-day half-life found for the long-acting research form.
Ipamorelin acts through the ghrelin receptor
Second, ipamorelin follows a different route. It triggers the ghrelin receptor, also called GHSR-1a. Therefore, researchers group it with GHRPs rather than GHRH analogues.
For context, an early animal and lab paper found that ipamorelin focused more on growth hormone release than older drugs in its class. However, that finding came mainly from non-human work. Therefore, it cannot prove that ipamorelin is safer in people.
Half-life and GH/IGF-1 duration side by side
In practice, the duration gap is large. In the 2006 Teichman study, researchers put the half-life of long-acting CJC-1295 at 5.8 to 8.1 days. Specifically, mean GH rose for at least six days after one injection. Meanwhile, mean IGF-1 stayed raised for nine to eleven days. Also, after repeat doses, mean IGF-1 stayed above its starting level for up to 28 days.
Conversely, the 1999 ipamorelin study included eight healthy men at each of five dose levels. In addition, researchers found a final half-life of about two hours. The GH response formed one episode, peaked at about 0.67 hours and then fell to very low levels.
What do the human studies actually show?
CJC-1295: hormone changes, not health benefits
The CJC-1295 studies looked at how long the peptide stayed in the body and how it changed hormone levels. For example, they measured half-life, GH, IGF-1 and GH pulse patterns. Also, a separate study found that GH pulses continued after CJC-1295, while average GH release rose.
Still, these studies did not test injury recovery, muscle gain, fat loss, anti-ageing results or long-term care. Moreover, the trials were small and included healthy adults. As a result, hormone changes cannot prove a real health benefit.
Ipamorelin: a brief GH response but no clear outcome benefit
The healthy-volunteer ipamorelin study also tracked how the body handled the drug and how GH changed. It found a dose-linked, short-lived GH episode. However, it did not prove recovery or body-composition benefits.
Subsequently, researchers tested ipamorelin through a vein after bowel surgery. However, the trial found no clear benefit in its main or extra outcome checks. Also, FDA has cited serious harms, including death, from use through a vein in that gut-motility programme. Therefore, it used those reports to explain its concerns about pharmacy-made ipamorelin.
Why are CJC-1295 and ipamorelin stacked?
The theory uses two receptor routes. In theory, CJC-1295 gives a GHRH-receptor signal, while ipamorelin gives a ghrelin-receptor signal. Indeed, earlier work with other GHRH and GHRP pairs found that the two classes could release more GH together than either class alone.
However, findings from a wider drug class are not direct proof for this exact pair. Moreover, no controlled human trial has compared CJC-1295 plus ipamorelin with a placebo or either drug alone. Likewise, researchers have not tested a combined plan against real health outcomes.
Therefore, the popular “baseline plus pulses” claim remains a theory. Consequently, it does not prove that the stack improves recovery, sleep, body composition or healthy ageing.
CJC-1295 No DAC + Ipamorelin
Baltic Peptides currently lists a combined CJC-1295 No DAC + Ipamorelin research product. It is the closest commercial match to the stack discussed above.
Affiliatevermelding: PeptideDeepDive may earn a commission from the supplier link. Price reflects shop data checked on 18 September 2026 and may change. Laboratory research only.
Is the CJC-1295 ipamorelin stack safe?
To begin with, no controlled study proves that the combination is safe. Using two unapproved products also adds more quality risks. For example, each item creates another chance of a wrong identity or strength, contamination, sterility faults or unwanted chemicals.
In addition, FDA has raised concerns about immunogenicity, peptide-related impurities and API characterisation for CJC-1295-related substances. FDA also says it identified serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction. Similarly, FDA lists ipamorelin acetate among bulk substances that may present significant safety risks for compounding. FDA notes potential immunogenicity, aggregation and peptide-related impurity concerns, and says it lacks sufficient safety information for certain injectable routes.
However, these concerns do not mean that every exposure causes harm. Instead, they show why small trials and online claims cannot prove long-term safety.
Are CJC-1295 and ipamorelin approved in Europe?
Neither CJC-1295 nor ipamorelin has EU-wide approval as a medicine. Likewise, neither has FDA approval in the United States. Therefore, neither drug has an approved use for recovery, anti-ageing, muscle gain or body-composition change.
European Union
Similarly, no EU-wide marketing authorisation exists for either drug. However, products sold to treat or prevent disease may fall under EU and national medicines law, despite a “research use only” label.
Ireland
For example, HPRA oversees medicines in Ireland. However, neither drug is an approved prescription medicine. Also, supply and advertising can trigger medicines-law rules.
United Kingdom
Meanwhile, neither drug has UK marketing authorisation. Furthermore, MHRA rules focus on how a product is presented, what it does, and how it is made and supplied.
Competitive sport
Finally, the 2026 WADA Prohibited List names both drugs in its growth-hormone section.
Importantly, “unapproved” does not always mean “illegal to possess.” National rules differ across Europe. Therefore, sale, import, advertising and intended use need a country-level legal check.
CJC-1295 vs Ipamorelin frequently asked questions
What is the main difference between CJC-1295 and ipamorelin?
CJC-1295 with DAC is a long-acting GHRH analogue. By contrast, ipamorelin is a short-acting peptide that triggers the ghrelin receptor. Therefore, they use different receptors before raising growth hormone release.
Why do people combine CJC-1295 with ipamorelin?
The theory is that GHRH-receptor and ghrelin-receptor signals may work together. However, no controlled human trial has tested this exact stack or proved better outcomes.
Which compound lasts longer?
The long-acting CJC-1295 form lasted much longer in human studies. Specifically, its half-life was about 5.8 to 8.1 days. By comparison, ipamorelin’s final half-life was about two hours in healthy volunteers.
Are CJC-1295 and ipamorelin approved medicines?
No. Similarly, neither has EU-wide marketing authorisation or FDA approval. Also, rules for supply, import and possession vary by country.
Are they prohibited by WADA?
Yes. The 2026 WADA list names CJC-1295 among GHRH analogues and ipamorelin among growth hormone secretagogues.
In the CJC-1295 vs Ipamorelin comparison, CJC-1295 gives a long GHRH-receptor signal. Meanwhile, ipamorelin produces a shorter GH episode through the ghrelin receptor. Therefore, human studies confirm those drug-level differences. However, they do not prove that the popular stack improves recovery, body composition or healthy ageing.
CJC-1295 With DAC (5mg / 10mg)
The commercial format most closely aligned with the long-acting DAC human literature discussed above.
Ipamorelin (5mg / 10mg)
A separate ghrelin-receptor research listing with its own evidence and safety profile.
CJC-1295 No DAC + Ipamorelin
The commercial combination most directly related to the stack section, but without published controlled human combination evidence.
Affiliatevermelding: PeptideDeepDive may earn a commission if you follow a supplier link. Prices reflect shop data checked on 18 September 2026 and may change. Listings are for laboratory research only and do not establish safety, efficacy or medicine approval.
References and primary sources
- Teichman et al. (2006): CJC-1295 GH and IGF-1 trial.
- Ionescu and Frohman (2006): CJC-1295 and GH pulse patterns.
- Raun et al. (1998): Early ipamorelin research.
- Gobburu et al. (1999): Ipamorelin in healthy volunteers.
- Beck et al. (2014): Ipamorelin after bowel surgery.
- ClinicalTrials.gov NCT00672074: Ipamorelin bowel-surgery trial.
- CJC-1295-related bulk drug substances: FDA review.
- Ipamorelin bulk drug substances: FDA review.
- Current FDA summary of bulk substances that may present safety risks.
- World Anti-Doping Agency: 2026 Prohibited List.
- EU Directive 2001/83/EC: medicines law.